vs
Side-by-side financial comparison of Dolby Laboratories, Inc. (DLB) and Enhabit, Inc. (EHAB). Click either name above to swap in a different company.
Dolby Laboratories, Inc. is the larger business by last-quarter revenue ($395.6M vs $270.4M, roughly 1.5× Enhabit, Inc.). Dolby Laboratories, Inc. runs the higher net margin — 24.0% vs -14.3%, a 38.3% gap on every dollar of revenue. On growth, Dolby Laboratories, Inc. posted the faster year-over-year revenue change (7.1% vs 4.7%). Over the past eight quarters, Dolby Laboratories, Inc.'s revenue compounded faster (13.9% CAGR vs 1.5%).
Dolby Laboratories, Inc. is an American technology corporation specializing in audio noise reduction, audio encoding/compression, spatial audio, and high-dynamic-range television (HDR) imaging. Dolby licenses its technologies to consumer electronics manufacturers.
Enhabit, Inc., is a Dallas, Texas-based provider of home health and hospice services. The company operates 255 home health and 110 hospice locations in 34 states with a concentration in Texas, Alabama, Florida, Georgia, Oklahoma and Mississippi. Enhabit is the fourth-largest provider of home health services in the United States and is a leading provider of hospice services. The company was formed in 2022 when Encompass Health spun off its home health and hospice business.
DLB vs EHAB — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $395.6M | $270.4M |
| Net Profit | $94.9M | $-38.7M |
| Gross Margin | 88.7% | — |
| Operating Margin | 28.5% | -12.3% |
| Net Margin | 24.0% | -14.3% |
| Revenue YoY | 7.1% | 4.7% |
| Net Profit YoY | 3.4% | 15.9% |
| EPS (diluted) | $0.99 | $-0.76 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 26 | $395.6M | — | ||
| Q1 26 | $346.7M | — | ||
| Q4 25 | $346.7M | $270.4M | ||
| Q3 25 | $307.0M | $263.6M | ||
| Q2 25 | $315.5M | $266.1M | ||
| Q1 25 | $369.6M | $259.9M | ||
| Q4 24 | $357.0M | $258.2M | ||
| Q3 24 | $304.8M | $253.6M |
| Q2 26 | $94.9M | — | ||
| Q1 26 | $53.3M | — | ||
| Q4 25 | $53.3M | $-38.7M | ||
| Q3 25 | $49.3M | $11.1M | ||
| Q2 25 | $46.1M | $5.2M | ||
| Q1 25 | $91.8M | $17.8M | ||
| Q4 24 | $67.8M | $-46.0M | ||
| Q3 24 | $58.6M | $-110.2M |
| Q2 26 | 88.7% | — | ||
| Q1 26 | 87.5% | — | ||
| Q4 25 | 87.5% | — | ||
| Q3 25 | 87.1% | — | ||
| Q2 25 | 86.1% | — | ||
| Q1 25 | 90.3% | — | ||
| Q4 24 | 88.6% | — | ||
| Q3 24 | 88.8% | — |
| Q2 26 | 28.5% | — | ||
| Q1 26 | 17.9% | — | ||
| Q4 25 | 17.9% | -12.3% | ||
| Q3 25 | 9.7% | 6.4% | ||
| Q2 25 | 15.1% | 6.3% | ||
| Q1 25 | 29.2% | 6.1% | ||
| Q4 24 | 22.4% | -16.0% | ||
| Q3 24 | 15.2% | -38.6% |
| Q2 26 | 24.0% | — | ||
| Q1 26 | 15.4% | — | ||
| Q4 25 | 15.4% | -14.3% | ||
| Q3 25 | 16.1% | 4.2% | ||
| Q2 25 | 14.6% | 2.0% | ||
| Q1 25 | 24.8% | 6.8% | ||
| Q4 24 | 19.0% | -17.8% | ||
| Q3 24 | 19.2% | -43.5% |
| Q2 26 | $0.99 | — | ||
| Q1 26 | $0.55 | — | ||
| Q4 25 | $0.55 | $-0.76 | ||
| Q3 25 | $0.50 | $0.22 | ||
| Q2 25 | $0.48 | $0.10 | ||
| Q1 25 | $0.94 | $0.35 | ||
| Q4 24 | $0.70 | $-0.92 | ||
| Q3 24 | $0.59 | $-2.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $594.7M | $43.6M |
| Total DebtLower is stronger | — | $426.0M |
| Stockholders' EquityBook value | $2.6B | $534.0M |
| Total Assets | $3.2B | $1.2B |
| Debt / EquityLower = less leverage | — | 0.80× |
8-quarter trend — quarters aligned by calendar period.
| Q2 26 | $594.7M | — | ||
| Q1 26 | $644.6M | — | ||
| Q4 25 | $644.6M | $43.6M | ||
| Q3 25 | $702.6M | $56.9M | ||
| Q2 25 | $699.3M | $37.1M | ||
| Q1 25 | $626.6M | $39.5M | ||
| Q4 24 | $520.8M | $28.4M | ||
| Q3 24 | $482.0M | $45.7M |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | — | $426.0M | ||
| Q3 25 | — | $441.5M | ||
| Q2 25 | — | $456.9M | ||
| Q1 25 | — | $467.3M | ||
| Q4 24 | — | $492.6M | ||
| Q3 24 | — | $502.9M |
| Q2 26 | $2.6B | — | ||
| Q1 26 | $2.6B | — | ||
| Q4 25 | $2.6B | $534.0M | ||
| Q3 25 | $2.6B | $566.8M | ||
| Q2 25 | $2.6B | $552.4M | ||
| Q1 25 | $2.6B | $543.2M | ||
| Q4 24 | $2.5B | $523.5M | ||
| Q3 24 | $2.5B | $566.1M |
| Q2 26 | $3.2B | — | ||
| Q1 26 | $3.2B | — | ||
| Q4 25 | $3.2B | $1.2B | ||
| Q3 25 | $3.2B | $1.2B | ||
| Q2 25 | $3.2B | $1.2B | ||
| Q1 25 | $3.2B | $1.2B | ||
| Q4 24 | $3.2B | $1.2B | ||
| Q3 24 | $3.1B | $1.3B |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | — | 0.80× | ||
| Q3 25 | — | 0.78× | ||
| Q2 25 | — | 0.83× | ||
| Q1 25 | — | 0.86× | ||
| Q4 24 | — | 0.94× | ||
| Q3 24 | — | 0.89× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $147.3M | $4.4M |
| Free Cash FlowOCF − Capex | — | $3.3M |
| FCF MarginFCF / Revenue | — | 1.2% |
| Capex IntensityCapex / Revenue | — | 0.4% |
| Cash ConversionOCF / Net Profit | 1.55× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $65.8M |
8-quarter trend — quarters aligned by calendar period.
| Q2 26 | $147.3M | — | ||
| Q1 26 | $54.8M | — | ||
| Q4 25 | $54.8M | $4.4M | ||
| Q3 25 | $472.2M | $37.8M | ||
| Q2 25 | $67.7M | $10.6M | ||
| Q1 25 | $174.9M | $17.9M | ||
| Q4 24 | $106.8M | $-4.1M | ||
| Q3 24 | $327.3M | $28.4M |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $50.2M | $3.3M | ||
| Q3 25 | $435.9M | $36.2M | ||
| Q2 25 | $61.3M | $8.7M | ||
| Q1 25 | $168.0M | $17.6M | ||
| Q4 24 | $100.0M | $-4.7M | ||
| Q3 24 | $297.2M | $27.7M |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 14.5% | 1.2% | ||
| Q3 25 | 142.0% | 13.7% | ||
| Q2 25 | 19.4% | 3.3% | ||
| Q1 25 | 45.5% | 6.8% | ||
| Q4 24 | 28.0% | -1.8% | ||
| Q3 24 | 97.5% | 10.9% |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 1.3% | 0.4% | ||
| Q3 25 | 11.8% | 0.6% | ||
| Q2 25 | 2.0% | 0.7% | ||
| Q1 25 | 1.9% | 0.1% | ||
| Q4 24 | 1.9% | 0.2% | ||
| Q3 24 | 9.8% | 0.3% |
| Q2 26 | 1.55× | — | ||
| Q1 26 | 1.03× | — | ||
| Q4 25 | 1.03× | — | ||
| Q3 25 | 9.57× | 3.41× | ||
| Q2 25 | 1.47× | 2.04× | ||
| Q1 25 | 1.91× | 1.01× | ||
| Q4 24 | 1.57× | — | ||
| Q3 24 | 5.59× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DLB
| Licensing | $372.2M | 94% |
| Products and services | $23.4M | 6% |
EHAB
| Third Party Payor Medicare | $111.6M | 41% |
| Third Party Payor Medicare Advantage | $67.5M | 25% |
| Hospice Segment | $63.6M | 24% |
| Third Party Payor Managed Care | $24.9M | 9% |
| Third Party Payor Medicaid | $1.7M | 1% |
